"The
Report PharmaPoint: Ulcerative Colitis - India Drug Forecast and
Market Analysis to 2022 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
During the forecast period from
2012-2022, the growth of the UC market will be driven largely by the
entry of Johnson & Johnsons (J&Js) Simponi and Takedas
Entyvio, which will lead to an increase in the overall number of
patients being treated with biologics in the US, 5EU, Japan, and
Canada. Another key event affecting the UC market is the anticipated
launch of biosimilars, given that the patent expiry of the UC
blockbusters, Remicade and Humira are set to expire in the US in 2018
and 2016, respectively.
It is worth noting that in
India, the local drug companies produce their own biosimilars,
without many regulatory guidelines or any regard for the patent
protection of the marketed products. For the treatment of UC, Indian
physicians rely heavily on non-pharmacological methods, such as
dietary recommendations, and for pharmacologic therapy, they use
generic products within the corticosteroids and 5-ASA classes.
GlobalDatas physician survey showed that these drugs are the mainstay
of treatment for mild to moderate UC in India, as well as at earlier
lines of therapy for severe disease.
View Report At
:http://www.marketresearchreports.biz/analysis/195933
Scope
- Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India Ulcerative Colitis market.
Reasons
to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/195933
Table
of Contents
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and
Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 15
3.2 Symptoms 17
3.2.1 Quality of Life 17
4 Disease Management 19
4.1 Diagnosis and Treatment
Overview 19
4.1.1 Diagnosis 19
4.1.2 Treatment Guidelines and
Leading Prescribed Drugs 23
4.1.3 Clinical Practice 24
4.2 India 28
5 Competitive Assessment 30
5.1 Overview 30
5.2 Strategic Competitor
Assessment 31
5.3 Product Profiles - Major
Brands 32
5.3.1 Remicade (infliximab) 32
5.3.2 Apriso (mesalamine) 39
5.3.3 Asacol HD (mesalamine) 43
5.3.4 Pentasa (mesalamine) 47
5.3.5 Other Drug Classes Used
in the Treatment of UC 50
5.4 Biosimilars 51
5.4.1 Introduction 51
5.4.2 Hospiras Inflectra Versus
J&Js Remicade in Key Autoimmune Diseases 52
5.4.3 Biosimilars in the
Immunology Community 52
5.4.4 By the Numbers:
Biosimilars in Development 53
5.4.5 The Impact of Biosimilars
Will be Felt Throughout the Pharmaceutical Industry 56
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment